Efficacy and safety of oral retinoids in different psoriasis subtypes: A systematic literature review

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue SUPPL. 2, 2011, Pages 28-33

  Sbidian, E ^a   Maza, A ^b   Montaudie H ^c   Gallini, A ^b   Aractingi, S ^d   Aubin, F ^e   Cribier, B ^f   Joly, P ^g   Jullien, D ^h   Le Maitre M ⁱ   Misery, L ^j   Richard, M A ^k   Paul, C ^b   Ortonne, J P ^c   Bachelez, H ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c UNIVERSITÉ CÔTE D'AZUR   (France)

^d HÔPITAL TENON   (France)

^e UNIVERSITY HOSPITAL OF BESANÇON   (France)

^f UNIVERSITÉ DE STRASBOURG   (France)

^g UNIVERSITÉ DE ROUEN   (France)

^h EDOUARD HERRIOT HOSPITAL   (France)

ⁱ Dermatologist   (France)

^j BREST UNIVERSITY HOSPITAL   (France)

^k TIMONE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ETRETIN; ETRETINATE; RETINOID;

BONE DISEASE; BONE TOXICITY; CLINICAL PROTOCOL; COCHRANE LIBRARY; DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; EMBASE; HUMAN; MEDLINE; META ANALYSIS; MONOTHERAPY; MUCOCUTANEOUS DISEASE; MUCOSAL DRYNESS; NAIL PSORIASIS; PHOTOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; PSORIASIS EN PLAQUE; PUSTULAR PSORIASIS; PUVA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; SKIN DISEASE; SYSTEMATIC REVIEW; TERATOGENICITY; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT;

EID: 79952549094     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.03993.x     Document Type: Review

References (64)

1. Davidovici BB, Sattar N, Jorg PC et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010; 130: 1785-1796.
2. Lebwohl M, Menter A, Koo J et al. Case studies in severe psoriasis: a clinical strategy. J Dermatolog Treat 2003; 14(Suppl. 2): 26-46. (Pubitemid 37474604)
3. Gollnick HP. Oral retinoids - efficacy and toxicity in psoriasis. Br J Dermatol 1996; 135(Suppl. 49): 6-17.
4. Paul C, Gourraud PA, Bronsard V et al. Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol 2010; 24(Suppl. 2): 2-9.
5. Paul C, Gallini A, Maza A et al. Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol 2011; 25(Suppl. 2): 2-11.
6. Berbis P, Geiger JM, Vaisse C et al. Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis. Dermatologica 1989; 178: 88-92. (Pubitemid 19058799)
7. Christiansen JV, Holm P, Moller R et al. Etretinate (Tigason) and beta-methasone valerate (Celeston valerate) in the treatment of psoriasis. A double-blind, randomized, multicenter trial. Dermatologica 1982; 165: 204-207.
8. Danno K, Sugie N. Combination therapy with low-dose etretinate and eicosapentaenoic acid for psoriasis vulgaris. J Dermatol 1998; 25: 703-705. (Pubitemid 28566705)
9. Dubertret L, Chastang C, Beylot C et al. Maintenance treatment of psoriasis by Tigason: a double-blind randomized clinical trial. Br J Dermatol 1985; 113: 323-330. (Pubitemid 15246608)
10. Ettler K, Richards B. Acitretin therapy for palmoplantar pustulosis combined with UVA and topical 8-MOP. Int J Dermatol 2001; 40: 541-542. (Pubitemid 33026318)
11. Ezquerra GM, Regana MS, Millet PU. Combination of acitretin and oral calcitriol for treatment of plaque-type psoriasis. Acta Derm Venereol 2007; 87: 449-450. (Pubitemid 351373434)
12. Finzi AF, Ippolito F, Panconesi E et al. Cyclosporin therapy in psoriasis: recommendations for treatment. Italian Multicenter Study Group on Cyclosporin in Psoriasis. Dermatology 1993; 187(Suppl. 1): 38-40. (Pubitemid 23223846)
13. Foged E, Holm P, Larsen PO et al. A randomized trial of etretinate (Tigason) in palmoplantar pustulosis. Dermatologica 1983; 166: 220-223. (Pubitemid 13119958)
14. Fredriksson T, Pettersson U. Oral treatment of pustulosis palmo-plantaris with a new retinoid, Ro 10-9359. Dermatologica 1979; 158: 60-64. (Pubitemid 9084747)
15. Giannetti A, Coppini M, Bertazzoni MG et al. Clinical trial of the efficacy and safety of oral etretinate with calcipotriol cream compared with etretinate alone in moderate-severe psoriasis. J Eur Acad Dermatol Venereol 1999; 13: 91-95. (Pubitemid 29472346)
16. Goldfarb MT, Ellis CN, Gupta AK et al. Acitretin improves psoriasis in a dose-dependent fashion. J Am Acad Dermatol 1988; 18: 655-662.
17. Gollnick H, Bauer R, Brindley C et al. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. J Am Acad Dermatol 1988; 19: 458-468.
18. Kingston TP, Matt LH, Lowe NJ. Etretin therapy for severe psoriasis. Evaluation of initial clinical responses. Arch Dermatol 1987; 123: 55-58.
19. Kragballe K, Jansen CT, Geiger JM et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Acta Derm Venereol 1989; 69: 35-40. (Pubitemid 19028329)
20. Lassus A, Geiger JM. Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial. Br J Dermatol 1988; 119: 755-759. (Pubitemid 19002627)
21. Lassus A, Geiger JM, Nyblom M et al. Treatment of severe psoriasis with etretin (RO 10-1670). Br J Dermatol 1987; 117: 333-341. (Pubitemid 17126010)
22. Lassus A, Lauharanta J, Eskelinen A. The effect of etretinate compared with different regimens of PUVA in the treatment of persistent palmoplantar pustulosis. Br J Dermatol 1985; 112: 455-459. (Pubitemid 15148491)
23. Lassus A, Lauharanta J, Juvakoski T et al. Efficacy of etretinate (Tigason) in clearing and prevention of relapse of palmoplantar pustulosis. Dermatologica 1983; 166: 215-219. (Pubitemid 13119957)
24. Lauharanta J, Geiger JM. A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis. Br J Dermatol 1989; 121: 107-112. (Pubitemid 19177127)
25. Lawrence CM, Marks J, Parker S et al. A comparison of PUVA-etretinate and PUVA-placebo for palmoplantar pustular psoriasis. Br J Dermatol 1984; 110: 221-226. (Pubitemid 14184214)
26. Ledo A, Martin M, Geiger JM et al. Acitretin (Ro 10-1670) in the treatment of severe psoriasis. A randomized double-blind parallel study comparing acitretin and etretinate. Int J Dermatol 1988; 27: 656-660. (Pubitemid 19000381)
27. Lowe NJ, Prystowsky JH, Bourget T et al. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 1991; 24: 591-594.
28. Mahrle G, Schulze HJ, Farber L et al. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995; 32: 78-88.
29. Matsunami E, Takashima A, Mizuno N et al. Topical PUVA, etretinate, and combined PUVA and etretinate for palmoplantar pustulosis: comparison of therapeutic efficacy and the influences of tonsillar and dental focal infections. J Dermatol 1990; 17: 92-96. (Pubitemid 20191472)
30. Meffert H, Sonnichsen N. Acitretin in the treatment of severe psoriasis: a randomized double-blind study comparing acitretin and etretinate. Acta Derm Venereol Suppl (Stockh) 1989; 146: 176-177. (Pubitemid 20013779)
31. Mittal R, Malhotra S, Pandhi P et al. Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol 2009; 145: 387-393.
32. Murray HE, Anhalt AW, Lessard R et al. A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study. J Am Acad Dermatol 1991; 24: 598-602.
33. Olsen EA, Weed WW, Meyer CJ et al. A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis. J Am Acad Dermatol 1989; 21: 681-686. (Pubitemid 19251725)
34. Orfanos CE, Steigleder GK, Pullmann H et al. Oral retinoid and UVB radiation: a new, alternative treatment for psoriasis on an out-patient basis. Acta Derm Venereol 1979; 59: 241-244. (Pubitemid 9172864)
35. Ozdemir M, Engin B, Baysal I et al. A randomized comparison of acitretin-narrow-band TL-01 phototherapy and acitretin-psoralen plus ultraviolet A for psoriasis. Acta Derm Venereol 2008; 88: 589-593.
36. Parker S, Coburn P, Lawrence C et al. A randomized double-blind comparison of PUVA-etretinate and PUVA-placebo in the treatment of chronic plaque psoriasis. Br J Dermatol 1984; 110: 215-220. (Pubitemid 14184213)
37. Pettit JH. Oral retinoid for psoriasis. A report of a double blind study. Acta Derm Venereol Suppl (Stockh) 1979; 59: 133-136.
38. Piraccini BM, Tosti A, Iorizzo M et al. Pustular psoriasis of the nails: treatment and long-term follow-up of 46 patients. Br J Dermatol 2001; 144: 1000-1005.
39. Rim JH, Park JY, Choe YB et al. The efficacy of calcipotriol + acitretin combination therapy for psoriasis: comparison with acitretin monotherapy. Am J Clin Dermatol 2003; 4: 507-510. (Pubitemid 36871768)
40. Rosen K, Mobacken H, Swanbeck G. PUVA, etretinate, and PUVA-etretinate therapy for pustulosis palmoplantaris. A placebo-controlled comparative trial. Arch Dermatol 1987; 123: 885-889.
41. Ruzicka T, Sommerburg C, Braun-Falco O et al. Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dermatol 1990; 126: 482-486. (Pubitemid 20128961)
42. Saurat JH, Geiger JM, Amblard P et al. Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis. Dermatologica 1988; 177: 218-224.
43. Tanew A, Guggenbichler A, Honigsmann H et al. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol 1991; 25: 682-684.
44. Thune P. Treatment of palmoplantar pustulosis with Tigason. Dermatologica 1982; 164: 67-72.
45. Tosti A, Ricotti C, Romanelli P et al. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 2009; 145: 269-271.
46. van de Kerkhof PC, Cambazard F, Hutchinson PE et al. The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol 1998; 138: 84-89. (Pubitemid 28077942)
47. White SI, Marks JM, Shuster S. Etretinate in pustular psoriasis of palms and soles. Br J Dermatol 1985; 113: 581-585. (Pubitemid 16205477)
48. White SI, Puttick L, Marks JM. Low-dose etretinate in the maintenance of remission of palmoplantar pustular psoriasis. Br J Dermatol 1986; 115: 577-582. (Pubitemid 16009012)
49. Wolska H, Jablonska S, Langner A et al. Etretinate therapy in generalized pustular psoriasis (Zumbusch type). Immediate and long-term results. Dermatologica 1985; 171: 297-304. (Pubitemid 16200738)
50. DiGiovanna JJ, Helfgott RK, Gerber LH et al. Extraspinal tendon and ligament calcification associated with long-term therapy with etretinate. N Engl J Med 1986; 315: 1177-1182. (Pubitemid 17056647)
51. Gilbert M, Ellis CN, Voorhees JJ. Lack of skeletal radiographic changes during short-term etretinate therapy for psoriasis. Dermatologica 1986; 172: 160-163. (Pubitemid 16167304)
52. Halkier-Sorensen L, Andresen J. A retrospective study of bone changes in adults treated with etretinate. J Am Acad Dermatol 1989; 20: 83-87. (Pubitemid 19033851)
53. Hohl D, Pelloni F, Sigg C et al. A prospective study of skeletal changes during short-term acitretin therapy. Dermatology 1992; 185: 23-26.
54. Kilcoyne RF. Effects of retinoids in bone. J Am Acad Dermatol 1988; 19: 212-216.
55. Kullavanijaya P, Kulthanan K. Clinical efficacy and side effects of acitretin on the disorders of keratinization: a one-year study. J Dermatol 1993; 20: 501-506. (Pubitemid 23274612)
56. Lee E, Koo J. Single-center retrospective study of long-term use of low-dose acitretin (Soriatane) for psoriasis. J Dermatolog Treat 2004; 15: 8-13. (Pubitemid 38252089)
57. Melnik B, Gluck S, Jungblut RM et al. Retrospective radiographic study of skeletal changes after long-term etretinate therapy. Br J Dermatol 1987; 116: 207-212. (Pubitemid 17008248)
58. Mork NJ, Kolbenstvedt A, Austad J. Skeletal side-effects of 5 years' acitretin treatment. Br J Dermatol 1996; 134: 1156-1157. (Pubitemid 26183159)
59. Okada N, Nomura M, Morimoto S et al. Bone mineral density of the lumbar spine in psoriatic patients with long term etretinate therapy. J Dermatol 1994; 21: 308-311. (Pubitemid 24225124)
60. Stern RS, Fitzgerald E, Ellis CN et al. The safety of etretinate as longterm therapy for psoriasis: results of the etretinate follow-up study. J Am Acad Dermatol 1995; 33: 44-52.
61. Torok L, Galuska L, Kasa M et al. Bone-scintigraphic examinations in patients treated with retinoids: a prospective study. Br J Dermatol 1989; 120: 31-36. (Pubitemid 19032888)
62. Van Dooren-Greebe RJ, Lemmens JA, De Boo T et al. Prolonged treatment with oral retinoids in adults: no influence on the frequency and severity of spinal abnormalities. Br J Dermatol 1996; 134: 71-76. (Pubitemid 26030996)
63. Vestergaard P, Rejnmark L, Mosekilde L. High-dose treatment with vitamin A analogues and risk of fractures. Arch Dermatol 2010; 146: 478-482.
64. Wilson DJ, Kay V, Charig M et al. Skeletal hyperostosis and extraosseous calcification in patients receiving long-term etretinate (Tigason). Br J Dermatol 1988; 119: 597-607.